GTCbio, Embassy Suites Boston at Logan Airport
May 8-9
DAY 1 - MAY 8, 2006
7:00 Registration & Breakfast
8:00 Opening Remarks: Paul Jackson, Johnson & Johnson (Conference Chair) SESSION 1 - New Technologies for Identifying Kinase Inhibitors
8:00 Leveraging X-ray Structural Information in Gene-family Based Drug Discovery: Application to Protein Kinases
Mark Jacobs, Vertex Pharmaceuticals 8:30 CADD Methods
Jessie English, Head of RTC Kinase, Pfizer Inc. 9:00 Industrialized Kinase Lead Discovery
Kirk McMillan, Exelixis
9:30 The Application of Chemical Dimerizers to Kinase Inhibitor Target Discovery
Nikolai Kley, GPCbiotech
10:00 Refreshment Break
10:30 Tracking the Regulation of Protein Kinases and Phosphorylation by Quantitative Antibody Microarrays and Multi-immunoblotting
Stephen Pelech, President & CEO, Kinexus
11:00 Keynote Presentation: Susan S. Taylor
Howard Hughes Medical Institute,
University of California, San Diego 12:00 Lunch 1:00 Tunable Scoring Functions and N-PLS in Structure-based Drug Design
Cornel Catana, Pfizer Inc.
1:30 The Use of Protein Microarrays in the Selectivity Profiling of Kinase Inhibitors
Henry Hepburne-Scott, Procognia Inc 2:00 Kinase Inhibitor de novo Design: How Much Structural Information is Enough?
Andy Jennings, Takeda San Diego
2:30 Kinase Selectivity Profiling as a Tool for Drug Discovery
Patrick Zarrinkar, Ambit Bioscience
3:00 Refreshment Break
SESSION 2 – Kinase Inhibitors as Anti-cancer Agents 3:15 The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases
Pete Connolly, Cancer Therapeutics Research, Johnson & Johnson
3:45 TBA
Graham Cheetam, Vertex
4:15 Refreshment Break
4:30 TGF beta RI Kinase (ALK 5) Inhibitors: In-vitro and In-vivo Characterization of a novel orally active pteridine SD-208
Jit Chakravarty, Director, Medicinal Chemistry, Scios Inc 5:00 Aurora Kinase Inhibitors
Nicola M. Heron, Astrazeneca
5:30 Sorafenib; A Novel Oral Multi-kinase Inhibitor
Mark Lynch, Bayer
6:00 Second-generation Kinase Inhibitors
Bert Klebl, GPC Biotech
6:30 Networking Reception/Poster Presentations
DAY 2 - MAY 9, 2006
8:00 Registration & Breakfast
8:15 Innovator's Breakfast:
Jun Wu, Nanostream 9:00 Recap of Day 2: Bridget Cole, Pfizer Inc.
SESSION 3– Kinase Inhibitors as Anti-inflammation Agents 9:15 Rho Kinase: A Target for Vascular Inflammation Chris Vlahos, Eli Lilly 9:45 PKCq as a therapeutic target for T-cell mediated diseases
Divya Chaudhary, Wyeth 10:15 Refreshment Break
10:45 The Biological Activity of p38alpha Inhibitors
Enrique Michelotti, Group Leader, Medicinal Chemistry, Locus Pharmaceuticals 11:15 Oral Presentations from Selected Abstracts 12:00 Lunch
SESSION 4 – Kinase Inhibitors as CNS Agents 1:00 Inhibitors of Cyclin-Dependent Kinase 5 in a Mouse Model of Neurodegeneration
Lily Moy, Harvard 1:30 Design of dual JNK3/p38 MAP kinase inhibitors for the treatment of stroke
Francesco G. Salituro, Director, Medicinal Chemistry
Vertex Pharmaceuticals
2:00 Novel Regulatory Mechanism of ErbB2 Function in Oligodendrocyte Differentiation by LINGO-1
Sha Mi, Principal Scientist, Discovery Biology, Biogen Idec 2:30 Refreshment Break 3:00 Visualization of Synaptic Ca2+ /calmodulin-dependent Protein Kinase II Activity in Living Neurons
Yasunori Hayashi, RIKEN-MIT Neuroscience Research Center, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology 3:30 Kinase Inhibitor Hit Finding
Mark Whittaker, Evotec 4:00 CONFERENCE CONCLUDES
|